Engineered immune cells take on Hard-to-Treat myeloma

NCT ID NCT05396885

Ongoing Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new type of CAR-T cell therapy, called CART-ddBCMA, in 136 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, modified to find and attack a protein called BCMA on myeloma cells. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CART-ddBCMA (anitocabtagene-autoleucel), a CAR-T cell therapy that targets BCMA on myeloma cells
What this could lead to: If it works, this could offer a powerful new option to control multiple myeloma that has stopped responding to other treatments, potentially leading to long-term remission.
What could go wrong: This is a phase 2 trial with 136 participants, so results are still early. CAR-T therapy can cause serious side effects like cytokine release syndrome and nerve problems, and the cancer may still return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
HonorHealth Cancer Transplant Institute

Scottsdale, Arizona, 85258, United States
Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, 84112, United States
John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Northside Hospital

Atlanta, Georgia, 30342, United States
Oregon Health & Science University (OHSU)

Portland, Oregon, 97239, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Wisconsin Clinical Science Center

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.